Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Tools Leading The Science Community to New Discoveries

Many of our technological advances are used first by the scientific community. Nuclear magnetic resonance machines to analyze molecular structures were turned in the MRI machine used in hospitals, for example. 3D printers were used by scientists before they entered industry. The internet was created for scientific usage before becoming more generally available to the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Many of our technological advances are used first by the scientific community. Nuclear magnetic resonance machines to analyze molecular structures were turned in the MRI machine used in hospitals, for example. 3D printers were used by scientists before they entered industry. The internet was created for scientific usage before becoming more generally available to the public, especially through the subsequent development of the world wide web.

So, what are scientists using these days?

Artificial Intelligence

One thing scientists are using more and more is artificial intelligence (AI). AI is being used in what is called augmented analytics to better analyze data and to find patterns that may not be as obvious to humans. Human-AI interactions are resulting in new theories and hypotheses to be tested in the lab. It will be interesting to see what happens as people in-turn put the results of those experiments back into the AI for further refinement of those theories and the development of even more testable hypotheses.

The amount of data collected for all things from science to business has entered the zettabyte era (that is sextillion bytes), meaning it is becoming increasingly impossible for humans to deal with it all. Only AI is even remotely capable of handling this amount of data—an amount which is only increasing each and every moment.

Quantum Computers

Machine learning is going to take a quantum leap the moment quantum computers become fully feasible—and that moment is rapidly approaching. Right now, it is well within the realm of scientific research, in no small part because of the problems with cooling such a system, but it is expected that quantum computing will become more widely available in the next several years.

In the meantime, the development of quantum computing itself will provide researchers with more scientific knowledge about quantum physics and how we can use that knowledge to create more powerful computers and AI. After all, we are still working out exactly how quantum computers do their calculations and knowing that will lead to the design of even better quantum computers.

Quantum computers will help scientists fully integrate complex data, better analyze complex systems and processes, and thus help make better pattern predictions for such systems. This will help not only the physical and biological sciences, but also the more complex social and psychological sciences where reductionist methods have proven less than sufficient to help us understand these processes.

Robots

Robotics is another area which will no doubt impact science. The continuing development of more refined movement will allow field scientists to use robots to reach places that might have otherwise been too dangerous for a human, and it will allow scientists in the lab to engage in more precise manipulations of living and physical objects. The development of soft robotics will further open up research possibilities in more difficult-to-reach areas.

Robotic process automation will also help scientists a great deal more. Many lab processes have been automated, but many more can be. This will free scientists up to do more research, to better keep up with the reading and to do more of the mental work of science rather than having to spend quite so much time doing simple repetitive jobs. The more such technology permeates, the more even the small labs at small colleges will be automated, and the more those scientists can contribute.

Technology is transforming science every bit as much as it does business and our personal lives. Usually, the scientists get the first shot at the most recent technological innovations, trying them out and using them to advance our knowledge. It is sometimes hard to imagine what can come out of scientific instruments—who would have expected body imaging from a chemical structure analysis tool? So long as people are free to think and innovate, we will continue to see technological advances emerging out of the lab and into our living rooms.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512